Analyst Profile

Followed by 172 followers
.
Joel Beatty

Joel Beatty

Robert W. Baird
Wall Street Analyst
#4,968 out of 8,160 Wall Street Analysts
#13,292 out of 24,427 experts

Success Rate

46%
131 out of 285 transactions made a profit

Average Return

0.00%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Joel Beatty's trades since 2016 and holding each position for 1 Year would result in 45.96% of your transactions generating a profit, with an average return of 0.0% per rating.

Stock Rating Distribution

409Ratings
73.35% Buy
22.49% Hold
4.16% Sell
Distribution of Joel Beatty's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Inovio Pharmaceuticals
(INO)
Rating:Buy
Date:Sep 15, 2019 - Sep 15, 2020
Return:+426.20%
The most profitable rating made by Joel Beatty

Joel Beatty's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
RPTP
Raptor Pharmaceutical Corp.
Aug 08, 2016
Hold
Downgraded
3Ratings
100%
+63.40%
DMTX
Dimension Therapeutics Inc
Oct 03, 2017
Hold
Upgraded
4Ratings
0%
-46.50%
Cidara Therapeutics
Jul 26, 2018
Buy
Initiated
$8.00
(1235.34% Upside)
1Ratings
0%
-64.40%
Astria Therapeutics
Aug 10, 2018
Buy
Reiterated
$15.00
(37.74% Upside)
6Ratings
0%
-48.03%
Novavax
May 06, 2019
Buy
Reiterated
$19.00
(15.01% Upside)
10Ratings
50%
+31.33%
Kura Oncology
May 24, 2019
Buy
Reiterated
$25.00
(56.25% Upside)
5Ratings
20%
+5.28%
ImmunityBio
May 30, 2019
Sell
Downgraded
$0.80
(-87.16% Downside)
6Ratings
50%
-112.33%
Solid Biosciences
Aug 29, 2019
Sell
Downgraded
$6.00
(-11.37% Downside)
5Ratings
100%
+74.97%
aTyr Pharma
Aug 30, 2019
Hold
Reiterated
$3.75
(62.34% Upside)
6Ratings
100%
+54.80%
Inovio Pharmaceuticals
Sep 15, 2019
Buy
Reiterated
$4.00
(102.02% Upside)
2Ratings
50%
+207.45%
List of latest recommendations made by Joel Beatty. Click to expand and see Joel Beatty's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >